
  
    
      
        Background_NNP
        Traditionally_RB ,_, techniques_NNS for_IN the_DT study_NN of_IN gene_NN
        expression_NN were_VBD significantly_RB limited_JJ in_IN both_DT breadth_NN and_CC
        efficiency_NN since_IN these_DT studies_NNS typically_RB allowed_VBN
        investigators_NNS to_TO study_VB only_RB one_CD or_CC a_DT few_JJ genes_NNS at_IN a_DT time_NN ._.
        However_RB ,_, the_DT recently_RB developed_VBN DNA_NNP microarray_NN technique_NN is_VBZ
        a_DT powerful_JJ method_NN that_WDT provides_VBZ researchers_NNS with_IN the_DT
        opportunity_NN to_TO analyze_VB the_DT expression_NN patterns_NNS of_IN tens_NNS of_IN
        thousands_NNS of_IN genes_NNS in_IN a_DT short_JJ time_NN [_NN 1_CD ]_NN ._. Presently_NNP ,_,
        several_JJ vendors_NNS offer_VBP these_DT microarray_NN systems_NNS ,_, also_RB known_VBN
        as_IN chips_NNS ,_, with_IN a_DT variety_NN of_IN technologies_NNS available_JJ ._.
        Currently_RB ,_, DNA_NNP microarrays_NNS are_VBP manufactured_VBN using_VBG either_CC
        cDNA_NN or_CC oligonucleotides_NNS as_IN gene_NN probes_NNS ._. cDNA_NN microarrays_NNS
        are_VBP created_VBN by_IN spotting_VBG amplified_VBN cDNA_NN fragments_NNS in_IN a_DT high_JJ
        density_NN pattern_NN onto_IN a_DT solid_JJ substrate_NN such_JJ as_IN a_DT glass_NN
        slide_NN [_NN 1_CD 2_CD ]_NN ._. Oligonucleotide_NNP arrays_NNS are_VBP either_CC spotted_VBN
        or_CC constructed_VBN by_IN chemically_RB synthesizing_VBG approximately_RB
        25_CD -_: mer_NN oligonucleotide_NN probes_NNS directly_RB onto_IN a_DT glass_NN or_CC
        silicon_NN surface_NN using_VBG photolithographic_JJ technology_NN [_NN 3_CD ]_NN
        ._.
        Due_JJ to_TO the_DT powerful_JJ nature_NN of_IN microarrays_NNS ,_, the_DT number_NN of_IN
        relevant_JJ publications_NNS in_IN this_DT burgeoning_VBG field_NN is_VBZ
        increasing_VBG exponentially_RB ._. During_IN the_DT years_NNS 1995_CD -_: 1997_CD ,_, the_DT
        number_NN of_IN reports_NNS featuring_VBG microarray_NN data_NNS was_VBD less_JJR than_IN
        ten_CD ._. However_RB ,_, in_IN 2001_CD alone_RB approximately_RB 800_CD publications_NNS
        featured_VBD data_NNS generated_VBN by_IN microarray_NN studies_NNS (_( according_VBG to_TO
        a_DT PubMed_NNP search_NN )_) ._.
        Microarray_NNP technology_NN certainly_RB has_VBZ the_DT potential_NN to_TO
        greatly_RB enhance_VB our_PRP$ knowledge_NN about_IN gene_NN expression_NN ,_, but_CC
        there_EX are_VBP drawbacks_NNS that_WDT need_VBP to_TO be_VB considered_VBN ._. As_IN Knight_NNP [_NN
        4_CD ]_NN cautioned_VBD ,_, it_PRP is_VBZ possible_JJ that_IN errors_NNS could_MD be_VB
        incorporated_VBN during_IN the_DT manufacture_NN of_IN the_DT chips_NNS ._.
        Consequently_RB ,_, the_DT fidelity_NN of_IN the_DT DNA_NNP fragments_NNS immobilized_JJ
        to_TO the_DT microarray_NN surface_NN may_MD be_VB compromised_VBN ._. However_RB ,_,
        there_EX are_VBP few_JJ studies_NNS where_WRB the_DT majority_NN of_IN the_DT gene_NN
        sequences_NNS spotted_VBD on_IN the_DT microarrays_NNS were_VBD verified_VBN [_NN 5_CD ]_NN ._.
        Kuo_NNP 
        et_CC al_NN (_( 2002_CD )_) compared_VBD the_DT data_NNS from_IN
        two_CD high-throughput_JJ DNA_NNP microarray_NN technologies_NNS ,_, cDNA_NN
        microarray_NN (_( Stanford_NNP type_NN )_) and_CC oligonucleotide_NN microarray_NN
        (_( from_IN Affymetrix_NNP )_) and_CC found_VBD very_RB little_JJ correlation_NN between_IN
        these_DT two_CD platforms_NNS [_NN 6_CD ]_NN ._. Unfortunately_RB ,_, many_JJ
        investigators_NNS are_VBP reporting_VBG microarray_NN data_NNS without_IN
        confirming_VBG their_PRP$ results_NNS by_IN other_JJ traditional_JJ gene_NN
        expression_NN techniques_NNS such_JJ as_IN PCR_NNP ,_, Northern_NNP blot_NN analysis_NN
        and_CC RNase_NNP protection_NN assay_NN ._. Raw_NNP microarray_NN data_NNS obtained_VBN
        from_IN questionable_JJ nucleotide_NN sequences_NNS are_VBP then_RB often_RB
        manipulated_VBN using_VBG cluster_NN and_CC statistical_JJ analysis_NN software_NN
        and_CC subsequently_RB reported_VBD in_IN scientific_JJ journals_NNS ._. In_IN
        addition_NN the_DT quality_NN of_IN the_DT probe_NN sequences_NNS and_CC the_DT
        location_NN of_IN the_DT probes_NNS selected_VBN for_IN incorporation_NN into_IN the_DT
        array_NN are_VBP also_RB very_RB important_JJ ._. For_IN example_NN ,_, if_IN probes_NNS are_VBP
        selected_VBN only_RB from_IN the_DT 3_CD '_POS end_NN of_IN a_DT given_VBN gene_NN ,_, then_RB there_EX
        is_VBZ a_DT strong_JJ possibility_NN that_IN different_JJ splice_NN variants_NNS of_IN
        that_DT gene_NN will_MD not_RB be_VB identified_VBN if_IN the_DT alternative_NN
        splicing_VBG occurs_VBZ at_IN the_DT 5_CD '_POS region_NN of_IN the_DT gene_NN ._.
        The_DT development_NN of_IN a_DT single_JJ chip_NN containing_VBG the_DT complete_JJ
        gene_NN set_VBN for_IN a_DT given_VBN tissue_NN or_CC for_IN a_DT complex_JJ organism_NN
        (_( 30_CD ,_, 000_CD to_TO 60_CD ,_, 000_CD genes_NNS )_) is_VBZ likely_JJ in_IN the_DT near_JJ future_JJ ,_, so_IN
        it_PRP is_VBZ paramount_JJ that_IN chip_NN manufacturers_NNS avoid_VBP these_DT
        problems_NNS [_NN 7_CD ]_NN ._. In_IN this_DT report_NN ,_, we_PRP demonstrate_VBP that_DT
        microarray_NN technology_NN continues_VBZ to_TO be_VB a_DT dynamic_JJ and_CC
        developing_VBG process_NN and_CC highlight_VB potential_JJ pitfalls_NNS that_WDT
        must_MD be_VB addressed_VBN when_WRB interpreting_VBG data_NNS ._.
      
      
        Results_NNS
        
          Inconsistent_NNP sequence_NN fidelity_NN of_IN spotted_JJ cDNA_NN
          microarrays_NNS
          cDNA_NN microarray_NN analysis_NN was_VBD performed_VBN using_VBG the_DT
          UniGEM-V_NNP chip_NN (_( IncyteGenomics_NNP ,_, Palo_NNP Alto_NNP ,_, CA_NNP )_) with_IN mRNA_NN
          isolated_VBN from_IN peripheral_JJ blood_NN mononuclear_NN cells_NNS (_( PBMC_NNP )_)
          of_IN a_DT large_JJ granular_JJ lymphocyte_NN leukemia_NN patient_NN and_CC a_DT
          healthy_JJ control_NN ._. In_IN this_DT microarray_NN ,_, 7075_CD immobilized_JJ
          cDNA_NN fragments_NNS (_( 4107_CD from_IN known_VBN genes_NNS and_CC 2968_CD ESTs_NNP )_) were_VBD
          immobilized_JJ onto_IN a_DT glass_NN slide_NN ._. After_IN careful_JJ examination_NN
          of_IN the_DT microarray_NN probes_NNS ,_, it_PRP was_VBD determined_VBN that_IN the_DT
          majority_NN of_IN the_DT spotted_VBN cDNA_NN fragments_NNS were_VBD from_IN the_DT 3_CD '_POS
          end_NN of_IN the_DT genes_NNS ._. Approximately_RB 80_CD up-regulated_JJ and_CC 12_CD
          down-regulated_JJ genes_NNS were_VBD identified_VBN in_IN leukemic_JJ LGL_NNP ._. We_PRP
          then_RB purchased_VBD seventeen_NN clones_NNS from_IN IncyteGenomics_NNP
          containing_VBG cDNA_NN fragments_NNS that_WDT represent_VBP fourteen_CD of_IN the_DT
          up-regulated_JJ and_CC three_CD of_IN the_DT down-regulated_JJ genes_NNS ._.
          Plasmid_NNP DNA_NNP was_VBD isolated_VBN from_IN the_DT clones_NNS and_CC the_DT
          sequences_NNS were_VBD verified_VBN ._. Unfortunately_RB ,_, we_PRP found_VBD several_JJ
          problems_NNS with_IN the_DT insert_NN DNA_NNP sequences_NNS in_IN these_DT clones_NNS ._.
          Four_CD of_IN the_DT seventeen_NN c_SYM DNA_NNP fragments_NNS spotted_VBD on_IN the_DT
          microarray_NN contained_VBD incorrect_JJ sequences_NNS (_( 23_CD ._. 5_LS %_NN )_) (_( Table_NNP
          1_LS )_) ._.
        
        
          Variable_NNP reliability_NN of_IN differential_NN expression_NN
          data_NNS
          The_DT cDNA_NN fragments_NNS corresponding_JJ to_TO differentially_RB
          expressed_VBD genes_NNS spotted_VBD on_IN the_DT microarrays_NNS were_VBD excised_VBN
          from_IN the_DT plasmid_NN DNA_NNP and_CC used_VBN as_IN probes_NNS in_IN Northern_NNP
          blots_NNS ._. Out_IN of_IN the_DT seventeen_NN only_RB eight_CD provided_VBN positive_JJ
          results_NNS as_IN indicated_VBN by_IN microarray_NN (_( 47_CD %_NN )_) ._. Although_IN all_PDT
          the_DT sequences_NNS for_IN the_DT down-regulated_JJ genes_NNS were_VBD correct_JJ ,_,
          Northern_NNP blot_NN analysis_NN with_IN these_DT probes_NNS did_VBD not_RB show_VB any_DT
          differential_NN expression_NN of_IN the_DT genes_NNS ._. This_DT is_VBZ in_IN contrast_NN
          to_TO the_DT microarray_NN data_NN that_WDT suggested_VBD they_PRP were_VBD down_RB
          regulated_VBN (_( Table_NNP 1_LS )_) ._.
        
        
          Low_NNP specificity_NN of_IN cDNA_NN microarray_NN probes_NNS
          By_IN microarray_NN analysis_NN ,_, it_PRP is_VBZ very_RB difficult_JJ to_TO
          distinguish_VB between_IN two_CD genes_NNS that_WDT share_NN a_DT high_JJ degree_NN of_IN
          sequence_NN similarity_NN ._. Low_NNP specificity_NN of_IN probes_NNS is_VBZ also_RB a_DT
          frequently_RB encountered_VBN problem_NN in_IN oligonucleotide_NN arrays_NNS ._.
          This_DT problem_NN is_VBZ especially_RB prevalent_JJ in_IN instances_NNS where_WRB
          DNA_NNP sequences_NNS are_VBP nearly_RB identical_JJ between_IN two_CD genes_NNS and_CC
          the_DT oligonucleotide_NN probes_NNS are_VBP generated_VBN from_IN the_DT 3_CD '_POS end_NN
          of_IN the_DT genes_NNS ._. For_IN example_NN ,_, the_DT 1_CD ._. 2_CD kb_NN fragment_NN (_( GB_NNP
          Accession_NNP No_UH ._. M_NNP 57888_CD )_) spotted_VBD on_IN the_DT cDNA_NN microarray_NN as_IN
          granzyme_NN B_NNP was_VBD not_RB able_JJ to_TO distinguish_VB between_IN 
          granzyme_NN B_NNP and_CC 
          H_NNP (_( Fig_NNP ._. 1_LS a_DT )_) ._. The_DT balanced_JJ
          differential_NN expression_NN of_IN 6_CD ._. 3_CD was_VBD calculated_VBN ._. A_DT probe_NN
          set_VBN was_VBD generated_VBN by_IN Affymetrix_NNP using_VBG the_DT similar_JJ
          sequence_NN information_NN (_( GB_NNP Accession_NNP No_UH ._. M_NNP 28879_CD )_) and_CC
          according_VBG to_TO oligonucleotide_NN array_NN ,_, 
          granzyme_NN B_NNP was_VBD shown_VBN to_TO be_VB
          up-regulated_JJ (_( fold_VB change_NN 21_CD ._. 5_LS :_: Fig_NNP ._. 1_LS b_SYM )_) ._. Northern_JJ blot_NN
          analysis_NN (_( using_VBG the_DT same_JJ fragment_NN as_IN probe_NN )_) did_VBD not_RB
          discriminate_JJ between_IN the_DT genes_NNS for_IN 
          granzyme_NN B_NNP versus_CC 
          granzyme_NN H_NNP (_( Fig_NNP ._. 1_LS c_SYM )_) ._. However_RB ,_, by_IN
          using_VBG gene-specific_JJ probes_NNS in_IN an_DT RNase_NNP protection_NN assay_NN ,_,
          we_PRP were_VBD able_JJ to_TO demonstrate_VB the_DT over-expression_JJ of_IN 
          granzyme_NN B_NNP and_CC 
          granzyme_NN H_NNP separately_RB in_IN leukemic_JJ
          LGL_NNP cells_NNS (_( Fig_NNP ._. 1_LS dand_NN 1_CD e_SYM )_) ._.
        
        
          Discrepancy_NNP in_IN fold_VB change_NN calculation_NN for_IN a_DT given_VBN
          gene_NN
          It_PRP is_VBZ very_RB difficult_JJ to_TO compare_VB the_DT exact_JJ fold_VB change_NN
          between_IN two_CD microarray_NN techniques_NNS ,_, and_CC no_DT standard_JJ value_NN
          system_NN is_VBZ currently_RB in_IN place_NN to_TO compare_VB the_DT changes_NNS found_VBD
          in_IN one_CD microarray_NN to_TO the_DT next_JJ ._. This_DT fact_NN was_VBD clearly_RB
          demonstrated_VBN by_IN Kuo_NNP et_CC al_NN (_( 2002_CD )_) in_IN their_PRP$ recent_JJ
          publication_NN [_NN 6_CD ]_NN ._. In_IN this_DT paper_NN we_PRP compared_VBD the_DT fold_VB
          change_NN (_( Affymetrix_NNP )_) and_CC balanced_JJ differential_NN expression_NN
          (_( cDNA_NN )_) with_IN Northern_NNP blot_NN expression_NN ._. For_IN example_NN ,_, our_PRP$
          IncyteGenomics_NNP cDNA_NN microarray_NN data_NNS demonstrated_VBN only_RB a_DT
          3_CD ._. 8_CD differential_NN expression_NN in_IN the_DT expression_NN of_IN 
          perforin_NN (_( Fig_NNP ._. 2_LS a_DT )_) ,_, a_DT pore-forming_JJ
          protein_NN produced_VBN by_IN cytolytic_JJ lymphocytes_NNS [_NN 8_CD ]_NN in_IN
          leukemic_JJ LGL_NNP cells_NNS ,_, whereas_IN the_DT oligonucleotide_NN
          microarray_NN indicated_VBD a_DT 103_CD fold_VB increase_NN (_( Fig_NNP ._. 2_LS b_SYM )_) ._. Using_VBG
          a_DT probe_NN identical_JJ to_TO the_DT one_CD spotted_VBD on_IN the_DT cDNA_NN
          microarray_NN ,_, we_PRP performed_VBD a_DT Northern_NNP blot_NN analysis_NN ._. The_DT
          blot_NN demonstrated_VBD the_DT up-regulation_JJ of_IN the_DT 
          perforin_NN transcript_NN in_IN leukemia_NN LGL_NNP
          cells_NNS (_( Fig_NNP ._. 2_LS c_SYM )_) ,_, but_CC the_DT fold_VB increase_NN was_VBD neither_DT 103_CD as_IN
          indicated_VBN by_IN oligonucleotide_NN array_NN nor_CC 3_CD ._. 8_CD as_IN determined_VBN
          by_IN the_DT cDNA_NN microarray_NN data_NNS ._. Instead_RB ,_, the_DT actual_JJ value_NN
          was_VBD determined_VBN to_TO fall_VB between_IN these_DT two_CD extreme_JJ values_NNS ._.
          These_DT observations_NNS strongly_RB suggest_VBP that_IN results_NNS for_IN
          significantly_RB altered_VBN genes_NNS should_MD be_VB confirmed_VBN with_IN
          other_JJ traditional_JJ techniques_NNS such_JJ as_IN Northern_NNP blots_NNS or_CC
          RNase_NNP protection_NN assays_NNS prior_RB to_TO reporting_VBG the_DT fold_VB
          increase_NN ._.
        
        
          Lack_NN of_IN probe_NN specificity_NN for_IN gene_NN isoforms_NNS
          One_CD of_IN the_DT genes_NNS spotted_VBD on_IN the_DT cDNA_NN microarray_NN that_IN
          we_PRP are_VBP interested_JJ in_IN is_VBZ (_( 
          Phosphatase_NNP in_IN Activated_NNP Cells_NNP )_) 
          PAC-_NNP 1_CD [_NN 9_CD ]_NN ._. The_DT differential_NN
          expression_NN of_IN 
          PAC-_NNP 1_CD by_IN both_DT cDNA_NN microarray_NN
          (_( differential_NN expression_NN 4_CD ._. 2_LS )_) and_CC oligonucleotide_NN arrays_NNS
          (_( fold_VB change_NN 1_CD ._. 6_CD )_) is_VBZ shown_VBN in_IN Figures_NNS 3_CD aand_NN 3_CD b_SYM ._. Using_VBG a_DT
          cDNA_NN fragment_NN identical_JJ to_TO the_DT 
          PAC-_NNP 1_CD probe_NN on_IN the_DT cDNA_NN microarray_NN ,_,
          we_PRP performed_VBD a_DT Northern_NNP blot_NN analysis_NN and_CC confirmed_VBD the_DT
          over-expression_JJ of_IN two_CD transcripts_NNS in_IN leukemic_JJ LGL_NNP cells_NNS
          (_( Fig_NNP ._. 3_LS c_SYM )_) ._. RT-PCR_NNP was_VBD performed_VBN using_VBG total_JJ RNA_NNP from_IN
          leukemic_JJ LGL_NNP and_CC specific_JJ probes_NNS designed_VBN to_TO amplify_VB
          full-length_JJ PAC-_NNP 1_CD ._. We_PRP did_VBD not_RB see_VB amplification_NN of_IN any_DT
          product_NN ._. In_IN addition_NN ,_, we_PRP found_VBD no_DT PAC-_NNP 1_CD expression_NN using_VBG
          two_CD different_JJ monoclonal_NN anti-_NN PAC-_NNP 1_CD antibodies_NNS in_IN Western_JJ
          blot_NN analysis_NN (_( data_NNS not_RB shown_VBN )_) ._. The_DT monoclonal_NN antibodies_NNS
          obtained_VBN from_IN Santa_NNP Cruz_NNP were_VBD based_VBN on_IN the_DT amino_JJ acid_NN
          sequence_NN information_NN obtained_VBN from_IN the_DT N-_NNP terminus_JJ and_CC
          C-_NNP terminus_JJ of_IN the_DT PAC-_NNP 1_CD ._. The_DT results_NNS of_IN all_PDT the_DT
          experiments_NNS did_VBD not_RB confirm_VB the_DT over-expression_JJ of_IN 
          PAC-_NNP 1_CD ._. Therefore_RB ,_, to_TO obtain_VB more_JJR
          information_NN about_IN the_DT structure_NN of_IN the_DT 
          PAC-_NNP 1_CD related_VBN genes_NNS in_IN leukemic_JJ
          LGL_NNP ,_, we_PRP screened_VBD an_DT LGL_NNP leukemia_NN cDNA_NN library_NN using_VBG a_DT 1_CD ._. 2_CD
          kb_NN 
          PAC-_NNP 1_CD cDNA_NN fragment_NN and_CC identified_VBN
          similar_JJ genes_NNS which_WDT are_VBP different_JJ forms_NNS of_IN 
          PAC-_NNP 1_CD (_( GenBank_NNP Accession_NNP #_# AF_NNP 331843_CD ,_,
          the_DT other_JJ sequence_NN is_VBZ not_RB deposited_VBN )_) ._. Similarly_RB an_DT
          anti-apoptotic_JJ gene_NN 
          A_DT 20_CD is_VBZ also_RB over-expressed_JJ in_IN
          leukemic_JJ LGL_NNP ,_, but_CC protein_NN expression_NN was_VBD absent_JJ when_WRB
          Western_JJ blots_NNS were_VBD performed_VBN with_IN monoclonal_NN antibodies_NNS
          raised_VBD against_IN the_DT amino_JJ acid_NN sequence_NN derived_VBN from_IN A_DT 20_CD
          (_( data_NNS not_RB shown_VBN )_) ._.
          Likewise_RB ,_, another_DT gene_NN of_IN interest_NN ,_, 
          NKG_NNP 2_CD C_NNP ,_, showed_VBD a_DT balanced_JJ
          differential_NN expression_NN of_IN 5_CD ._. 5_CD (_( Fig_NNP ._. 4_LS a_DT )_) ._. By_IN using_VBG a_DT
          probe_NN derived_VBN from_IN an_DT 
          NKG_NNP 2_CD C_NNP clone_NN ,_, we_PRP identified_VBD a_DT
          number_NN of_IN transcripts_NNS by_IN Northern_NNP blot_NN analysis_NN (_( Fig_NNP ._.
          4_LS b_SYM )_) ._. In_IN order_NN to_TO ascertain_VB more_RBR structural_JJ information_NN ,_,
          we_PRP again_RB screened_VBD the_DT LGL_NNP leukemia_NN library_NN and_CC identified_VBD
          the_DT presence_NN of_IN several_JJ members_NNS of_IN the_DT 
          NKG_NNP 2_CD gene_NN family_NN including_VBG 
          NKG_NNP 2_CD A_DT ,_, NKG_NNP 2_CD D_NNP ,_, NKG_NNP 2_CD E_NNP and_CC 
          NKG_NNP 2_CD F_NN (_( GB_NNP Accession_NNP Nos_NNP ._. AF_NNP 461812_CD ,_,
          AF_NNP 461811_CD ,_, AF_NNP 461157_CD )_) [_NN 10_CD ]_NN ._. Therefore_RB ,_, if_IN genes_NNS similar_JJ
          to_TO 
          NKG_NNP 2_CD family_NN members_NNS are_VBP spotted_VBN on_IN
          a_DT microarray_NN ,_, it_PRP may_MD be_VB difficult_JJ to_TO confirm_VB which_WDT form_VBP
          of_IN the_DT gene_NN is_VBZ differentially_RB expressed_VBN in_IN a_DT given_VBN
          sample_NN ._.
        
        
          Mismatch_NNP probe_NN sets_NNS mask_NN the_DT perfect_JJ match_NN signals_NNS
          in_IN oligonucleotide_NN array_NN (_( Affymetrix_NNP )_)
          In_IN order_NN to_TO accomplish_VB the_DT highest_JJS sensitivity_NN and_CC
          specificity_NN in_IN the_DT presence_NN of_IN a_DT complex_JJ background_NN ,_,
          Affymetrix_NNP introduced_VBD a_DT system_NN that_WDT entails_VBZ the_DT use_NN of_IN a_DT
          series_NN of_IN specific_JJ and_CC non-specific_JJ gene_NN probe_NN sets_NNS that_WDT
          are_VBP intended_VBN to_TO result_VB in_IN a_DT more_RBR accurate_JJ discrimination_NN
          between_IN true_JJ signal_NN and_CC random_JJ hybridization_NN ._. Each_DT probe_NN
          set_VBN consists_VBZ of_IN a_DT pair_NN of_IN 25_CD -_: mer_NN probes_NNS ,_, one_CD that_WDT
          represents_VBZ a_DT perfect_JJ match_NN (_( PM_NNP )_) to_TO the_DT mRNA_NN of_IN interest_NN ,_,
          and_CC a_DT second_JJ probe_NN differing_VBG by_IN only_RB one_CD nucleotide_NN ,_, the_DT
          mismatch_NN (_( MM_NNP )_) ._. The_DT mismatch_NN in_IN the_DT middle_JJ position_NN
          theoretically_RB provides_VBZ maximal_NN disruption_NN of_IN
          hybridization_NN ._. Unfortunately_RB ,_, the_DT use_NN of_IN the_DT mismatch_NN
          probe_NN information_NN can_MD interfere_VB with_IN fold_VB change_NN
          calculations_NNS of_IN gene_NN expression_NN ._. For_IN example_NN ,_, 
          perforin_NN transcripts_NNS showed_VBD strong_JJ
          hybridization_NN to_TO both_DT PM_NNP and_CC MM_NNP probe_NN sets_NNS ._. As_IN a_DT
          consequence_NN ,_, the_DT strong_JJ MM_NNP signal_NN masked_VBD the_DT PM_NNP signal_NN
          resulting_VBG in_IN a_DT low_JJ expression_NN readout_NN ,_, even_RB though_IN the_DT
          gene_NN was_VBD present_JJ in_IN normal_JJ PBMC_NNP (_( Fig_NNP ._. 2_LS b_SYM )_) ._. Therefore_RB ,_, the_DT
          subsequently_RB calculated_VBN fold_VB increase_NN from_IN the_DT test_NN
          sample_NN was_VBD extraordinarily_RB high_JJ and_CC deemed_VBN unreliable_JJ ._.
          Similarly_RB ,_, the_DT fold_VB change_NN calculation_NN was_VBD underestimated_VBN
          for_IN 
          PAC-_NNP 1_CD due_JJ to_TO the_DT strong_JJ signal_NN
          displayed_VBN for_IN MM_NNP probe_NN set_VBN (_( Fig_NNP ._. 3_LS b_SYM )_) ._. Genes_NNP such_JJ 
          as_IN human_JJ auto-antigen_JJ (_( GenBank_NNP
          Accession_NNP #_# L_NNP 26339_CD )_) and_CC 
          carboxyl_NN ester_NN lipase-like_JJ
          protein_NN (_( GenBank_NNP Accession_NNP #_# L_NNP 14813_CD )_) ,_, are_VBP additional_JJ
          examples_NNS where_WRB these_DT genes_NNS are_VBP present_JJ in_IN LGL_NNP sample_NN ,_, but_CC
          because_IN of_IN the_DT strong_JJ signals_NNS associated_VBN with_IN some_DT of_IN the_DT
          MM_NNP probes_NNS ,_, they_PRP are_VBP considered_VBN absent_JJ in_IN the_DT samples_NNS
          (_( Fig_NNP ._. 5_LS aand_NN 5_CD b_SYM )_) ._.
        
      
      
        Discussion_NNP
        In_IN order_NN to_TO identify_VB the_DT differentially_RB expressed_VBN genes_NNS
        in_IN large_JJ granular_JJ lymphocytic_JJ (_( LGL_NNP )_) leukemia_NN ,_, we_PRP performed_VBD
        microarray_NN analysis_NN using_VBG the_DT UniGEM-V_NNP microarray_NN from_IN
        IncyteGenomics_NNP and_CC the_DT HU_NNP 6800_CD oligonucleotide_NN array_NN from_IN
        Affymetrix_NNP ._. In_IN the_DT course_NN of_IN our_PRP$ analysis_NN ,_, we_PRP discovered_VBD
        several_JJ problems_NNS that_IN we_PRP feel_VBP could_MD occur_VB in_IN other_JJ studies_NNS
        that_WDT might_MD lead_VB to_TO false_JJ conclusions_NNS ._.
        Approximately_RB 80_CD up-regulated_JJ genes_NNS and_CC 12_CD
        down-regulated_JJ genes_NNS were_VBD identified_VBN by_IN cDNA_NN microarray_NN
        analysis_NN in_IN leukemic_JJ LGL_NNP cells_NNS ._. Since_IN microarray_NN technology_NN
        was_VBD a_DT new_JJ tool_NN at_IN that_DT time_NN ,_, we_PRP decided_VBD to_TO verify_VB the_DT
        sequences_NNS of_IN all_PDT the_DT genes_NNS that_WDT were_VBD differentially_RB
        expressed_VBN ._. To_TO that_DT end_NN ,_, we_PRP purchased_VBD approximately_RB 20_CD
        clones_NNS representing_VBG the_DT differentially_RB expressed_VBN genes_NNS and_CC
        verified_VBN the_DT sequences_NNS ._. We_PRP found_VBD that_IN only_RB approximately_RB
        70_CD %_NN of_IN the_DT genes_NNS spotted_VBD on_IN the_DT microarray_NN matched_VBD the_DT
        correct_JJ sequence_NN of_IN the_DT clones_NNS ._. Other_JJ groups_NNS reported_VBD
        similar_JJ observations_NNS ._. For_IN example_NN ,_, IMAGE_NNP mouse_NN cDNA_NN clones_NNS
        (_( approximately_RB 1200_CD )_) were_VBD purchased_VBN from_IN Research_NNP Genetics_NNP
        (_( Huntsville_NNP ,_, Alabama_NNP )_) and_CC sequences_NNS were_VBD verified_VBN by_IN
        Halgren_NNP 
        et_CC al_NN [_NN 11_CD ]_NN ._. This_DT group_NN found_VBD that_IN
        only_RB 62_CD %_NN were_VBD definitely_RB identified_VBN as_IN a_DT pure_JJ sample_NN of_IN the_DT
        correct_JJ clones_NNS ._. In_IN another_DT study_NN ,_, PCR_NNP amplification_NN
        products_NNS (_( previously_RB sequence-verified_JJ cDNA_NN clones_NNS )_) were_VBD
        re-sequenced_JJ and_CC only_RB 79_CD %_NN of_IN the_DT clones_NNS matched_VBD the_DT
        original_JJ database_NN [_NN 12_CD ]_NN ._. In_IN a_DT different_JJ study_NN ,_, it_PRP was_VBD
        estimated_VBN that_IN only_RB 80_CD %_NN of_IN the_DT genes_NNS in_IN a_DT set_NN of_IN microarray_NN
        experiments_NNS were_VBD correctly_RB identified_VBN [_NN 5_CD ]_NN ._. Therefore_RB ,_, we_PRP
        advise_VBP that_IN when_WRB preparing_VBG cDNA_NN microarrays_NNS (_( commercial_NN or_CC
        homemade_NN )_) ,_, it_PRP is_VBZ necessary_JJ to_TO sequence_NN verify_VB each_DT clone_NN at_IN
        the_DT final_JJ stage_NN before_IN printing_VBG the_DT microarray_NN ._. If_IN mistakes_NNS
        are_VBP made_VBN at_IN this_DT stage_NN ,_, it_PRP is_VBZ not_RB possible_JJ to_TO correct_VB them_PRP
        later_RB by_IN using_VBG the_DT most_RBS sophisticated_JJ analytical_JJ tools_NNS ._.
        We_PRP used_VBD cDNA_NN microarray_NN analysis_NN to_TO compare_VB the_DT gene_NN
        expression_NN profile_NN of_IN leukemic_JJ LGL_NNP cells_NNS obtained_VBN from_IN a_DT
        patient_NN versus_CC the_DT expression_NN profile_NN of_IN PBMC_NNP obtained_VBD from_IN
        a_DT normal_JJ healthy_JJ individual_NN as_IN a_DT control_NN ._. We_PRP decided_VBD to_TO
        verify_VB the_DT microarray_NN results_NNS using_VBG samples_NNS from_IN more_JJR
        patients_NNS by_IN employing_VBG the_DT use_NN of_IN other_JJ methods_NNS such_JJ as_IN PCR_NNP ,_,
        Northern_NNP blot_NN and_CC RNase_NNP protection_NN assay_NN ._. To_TO our_PRP$ surprise_NN ,_,
        none_NN of_IN the_DT three_CD down-regulated_JJ genes_NNS studied_VBN exhibited_VBN
        differential_NN expression_NN in_IN Northern_NNP blots_NNS when_WRB the_DT cDNA_NN
        fragments_NNS of_IN these_DT genes_NNS were_VBD used_VBN as_IN probes_NNS ._. In_IN the_DT
        up-regulated_JJ genes_NNS ,_, only_RB 47_CD %_NN proved_VBD to_TO support_VB the_DT results_NNS
        from_IN the_DT microarray_NN data_NN ._. The_DT rest_NN either_CC displayed_VBD no_DT
        signal_NN ,_, were_VBD not_RB detectable_JJ in_IN any_DT sample_NN or_CC failed_VBD to_TO
        reveal_VB any_DT differential_NN expression_NN whatsoever_RB ._. Although_IN
        some_DT genes_NNS such_JJ as_IN 
        PAC-_NNP 1_CD and_CC 
        A_DT 20_CD showed_VBD differential_NN expression_NN in_IN
        LGL_NNP leukemia_NN patients_NNS ,_, no_DT product_NN amplification_NN was_VBD
        obtained_VBN using_VBG RT-PCR_NNP with_IN gene-specific_JJ primers_NNS ._.
        By_IN microarray_NN analysis_NN ,_, it_PRP is_VBZ very_RB difficult_JJ to_TO
        distinguish_VB between_IN two_CD similar_JJ genes_NNS ._. The_DT best_JJS example_NN in_IN
        our_PRP$ case_NN is_VBZ when_WRB 
        granzyme_NN B_NNP and_CC 
        granzyme_NN H_NNP are_VBP compared_VBN ._. These_DT two_CD
        genes_NNS share_VBP approximately_RB 80_CD %_NN similarity_NN at_IN the_DT DNA_NNP level_NN
        but_CC have_VBP different_JJ enzymatic_JJ activities_NNS [_NN 13_CD 14_CD ]_NN ._. Using_VBG
        either_CC one_CD of_IN the_DT genes_NNS as_IN a_DT probe_NN ,_, both_DT cDNA_NN microarray_NN
        and_CC northern_JJ blot_NN analysis_NN indicated_VBD over-expression_JJ of_IN
        both_DT genes_NNS indiscriminately_RB (_( Fig_NNP ._. 1_LS )_) ._. However_RB ,_, using_VBG
        gene-specific_JJ probes_NNS in_IN an_DT RNase_NNP protection_NN assay_NN ,_, we_PRP were_VBD
        able_JJ to_TO distinctly_RB identify_VB the_DT over-expression_JJ of_IN both_DT 
        granzyme_NN B_NNP and_CC 
        H_NNP in_IN leukemic_JJ LGL_NNP cells_NNS (_( Fig_NNP ._. 1_LS dand_NN
        1_CD e_SYM )_) ._. In_IN normal_JJ PBMC_NNP only_RB trace_VB amounts_NNS of_IN both_DT genes_NNS were_VBD
        identified_VBN ,_, but_CC after_IN activation_NN by_IN PHA_NNP and_CC IL_NNP 2_CD only_RB 
        granzyme_NN B_NNP was_VBD up-regulated_JJ ._. It_PRP is_VBZ
        very_RB difficult_JJ to_TO get_VB this_DT information_NN by_IN microarray_NN
        analysis_NN alone_RB ._. Therefore_RB ,_, caution_NN in_IN presenting_VBG microarray_NN
        data_NNS without_IN verification_NN and_CC confirmation_NN is_VBZ advised_VBN ._.
        When_WRB the_DT results_NNS from_IN two_CD different_JJ microarray_NN
        technologies_NNS (_( cDNA_NN and_CC oligonucleotide_NN arrays_NNS )_) were_VBD
        compared_VBN ,_, the_DT differential_NN expression_NN in_IN some_DT of_IN the_DT genes_NNS
        appeared_VBD to_TO agree_VB in_IN both_DT cases_NNS but_CC a_DT large_JJ variation_NN in_IN
        expression_NN profiles_NNS between_IN the_DT two_CD microarrays_NNS was_VBD clearly_RB
        evident_JJ ._. Previously_RB ,_, such_JJ systematic_JJ differences_NNS in_IN the_DT two_CD
        technologies_NNS were_VBD reported_VBN [_NN 6_CD ]_NN ._. For_IN example_NN ,_, 
        perforin_NN showed_VBD a_DT 103_CD -_: fold_VB change_NN in_IN
        the_DT Affymetrix_NNP array_NN ,_, whereas_IN the_DT cDNA_NN microarray_NN showed_VBD
        only_RB a_DT balanced_JJ differential_NN expression_NN of_IN 3_CD ._. 8_CD -_: fold_VB ._.
        Northern_JJ blot_NN results_NNS indicate_VBP that_IN the_DT genes_NNS were_VBD
        over-expressed_JJ ,_, but_CC the_DT actual_JJ value_NN is_VBZ in_IN between_IN the_DT
        values_NNS from_IN the_DT two_CD microarrays_NNS ._. This_DT problem_NN may_MD be_VB due_JJ to_TO
        an_DT inaccurate_JJ fold_VB change_NN calculation_NN due_JJ to_TO the_DT inclusion_NN
        of_IN mismatch_NN values_NNS in_IN the_DT formula_NN ._. We_PRP observed_VBD that_IN many_JJ
        over-expressed_JJ genes_NNS were_VBD not_RB properly_RB identified_VBN at_IN times_NNS ._.
        This_DT may_MD be_VB the_DT result_NN of_IN the_DT introduction_NN of_IN mismatch_NN
        values_NNS in_IN the_DT Affymetrix_NNP system_NN ._. For_IN example_NN ,_, genes_NNS for_IN 
        human_JJ autoantigen_NN and_CC 
        human_JJ carboxyl_NN ester_NN lipase-like_JJ
        protein_NN would_MD be_VB considered_VBN up-regulated_JJ in_IN the_DT
        microarray_NN (_( according_VBG to_TO PM_NNP match_VB hybridization_NN )_) if_IN the_DT MM_NNP
        hybridization_NN values_NNS were_VBD ignored_VBN in_IN the_DT fold_VB change_NN
        calculation_NN ._.
        DNA_NN microarray_NN anlysis_NNS can_MD be_VB a_DT powerful_JJ technique_NN to_TO
        identify_VB differentially_RB expressed_VBD genes_NNS but_CC differentiating_VBG
        between_IN splice_NN variants_NNS can_MD be_VB problematic_JJ ._. For_IN example_NN ,_,
        although_IN the_DT differential_NN expression_NN of_IN the_DT several_JJ genes_NNS
        such_JJ as_IN 
        PAC-_NNP 1_CD and_CC 
        A_DT 20_CD were_VBD confirmed_VBN by_IN northern_JJ blot_NN
        analysis_NN ,_, we_PRP were_VBD unable_JJ to_TO see_VB any_DT expression_NN of_IN protein_NN
        corresponding_JJ to_TO these_DT genes_NNS by_IN Western_JJ blot_NN analysis_NN ._. We_PRP
        were_VBD also_RB unable_JJ to_TO amplify_VB those_DT genes_NNS using_VBG gene-specific_JJ
        primers_NNS by_IN RT-PCR_NNP ._. After_IN screening_VBG the_DT LGL_NNP library_NN ,_, we_PRP
        obtained_VBD several_JJ full-length_JJ genes_NNS that_WDT were_VBD different_JJ from_IN
        both_DT the_DT 5_CD '_POS and_CC 3_CD '_POS ends_NNS of_IN 
        PAC_NNP 1_CD ._. Similarly_RB ,_, we_PRP screened_VBD an_DT LGL_NNP
        leukemia_NN library_NN and_CC obtained_VBN several_JJ 1_CD ._. 5_CD kb_NN cDNA_NN fragments_NNS
        using_VBG the_DT 
        A_DT 20_CD cDNA_NN as_IN a_DT probe_NN ._. The_DT deduced_JJ
        amino_JJ acid_NN sequences_NNS of_IN these_DT genes_NNS revealed_VBD different_JJ
        proteins_NNS ._.
        We_PRP found_VBD an_DT up-regulation_JJ of_IN 
        NKG_NNP 2_CD C_NNP with_IN a_DT balanced_JJ differential_NN
        expression_NN of_IN 5_CD ._. 8_CD in_IN cDNA_NN microarray_NN (_( Fig_NNP ._. 4_LS a_DT )_) ._. When_WRB
        Northern_NNP Blot_NNP analysis_NN was_VBD performed_VBN using_VBG 
        NKG_NNP 2_CD C_NNP cDNA_NN as_IN a_DT probe_NN ,_, we_PRP identified_VBD
        multiple_JJ transcripts_NNS ._. Screening_NNP the_DT LGL_NNP leukemia_NN library_NN
        resulted_VBD in_IN the_DT identification_NN of_IN several_JJ other_JJ members_NNS of_IN
        the_DT 
        NKG_NNP 2_CD family_NN such_JJ as_IN 
        NKG_NNP 2_CD A_DT ,_, D_NNP ,_, E_NNP ,_, and_CC 
        F_NN [_NN 10_CD ]_NN ._. Therefore_RB ,_, it_PRP can_MD be_VB very_RB
        difficult_JJ to_TO distinguish_VB different_JJ forms_NNS of_IN genes_NNS if_IN they_PRP
        are_VBP similar_JJ in_IN certain_JJ sequence_NN regions_NNS ._.
      
      
        Conclusions_NNP
        At_IN the_DT time_NN of_IN writing_VBG this_DT report_NN there_EX were_VBD
        approximately_RB 1150_CD articles_NNS published_VBD describing_VBG microarray_NN
        results_NNS (_( PubMed_NNP )_) ._. There_EX is_VBZ no_DT doubt_NN that_IN these_DT results_NNS will_MD
        provide_VB an_DT overall_JJ idea_NN of_IN gene_NN expression_NN and_CC contribute_VB
        to_TO understanding_VBG the_DT molecular_JJ mechanisms_NNS involved_VBN in_IN
        various_JJ processes_NNS ._. However_RB ,_, as_IN demonstrated_VBN by_IN our_PRP$
        findings_NNS ,_, the_DT development_NN of_IN a_DT standardized_JJ microarray_NN
        system_NN is_VBZ needed_VBN to_TO obtain_VB more_RBR meaningful_JJ data_NNS from_IN these_DT
        experiments_NNS ._. The_DT introduction_NN of_IN more_JJR uniform_NN systems_NNS
        combined_VBN with_IN the_DT consideration_NN of_IN the_DT above_JJ described_VBD
        pitfalls_NNS and_CC alternatives_NNS will_MD allow_VB better_JJR utilization_NN of_IN
        this_DT powerful_JJ technique_NN in_IN an_DT expanding_VBG collection_NN of_IN
        scientific_JJ endeavors_NNS ._. It_PRP will_MD be_VB very_RB helpful_JJ for_IN the_DT
        scientific_JJ community_NN if_IN the_DT verified_VBN data_NN is_VBZ deposited_VBN in_IN a_DT
        public_JJ data_NN base_VBP ._.
      
      
        Methods_NNP
        
          Isolation_NNP of_IN PBMC_NNP and_CC RNA_NNP
          PBMC_NNP were_VBD isolated_VBN from_IN whole_JJ blood_NN using_VBG
          Ficoll-_NNP Hypaque_NNP density_NN gradient_NN centrifugation_NN ._. These_DT
          cells_NNS were_VBD suspended_VBN in_IN Trizol_NNP reagent_NN (_( GIBCO-BRL_NNP ,_,
          Rockville_NNP ,_, MD_NNP )_) and_CC total_JJ RNA_NNP was_VBD isolated_VBN immediately_RB
          according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._. Poly_NNP A_DT +_NN RNA_NNP
          was_VBD isolated_VBN from_IN total_JJ RNA_NNP by_IN using_VBG Oligo-_NNP Tex_NNP mini_NN mRNA_NN
          kit_NN (_( Qiagen_NNP ,_, Valencia_NNP ,_, CA_NNP )_) according_VBG to_TO the_DT
          manufacturer_NN 's_POS recommendations_NNS ._.
        
        
          Activation_NNP of_IN PBMC_NNP
          Normal_NNP PBMC_NNP were_VBD cultured_JJ 
          in_IN vitro_NN and_CC activated_VBN by_IN PHA_NNP ,_,
          (_( Sigma_NNP Chemical_NNP Co_NNP ._. St_NNP ._. Louis_NNP ,_, MO_NNP )_) (_( 1_CD μg_NN /_NN ml_NN ,_, 2_CD days_NNS )_) and_CC
          Interleukin-_NNP 2_CD (_( IL-_NNP 2_LS )_) (_( 100_CD U_NNP /_NN ml_NN ,_, 10_CD days_NNS )_) ,_, then_RB total_JJ RNA_NNP
          was_VBD isolated_VBN ._.
        
        
          cDNA_NN microarray_NN analysis_NN
          Microarray_NNP probing_VBG and_CC analysis_NN was_VBD performed_VBN by_IN
          IncyteGenomics_NNP ._. Briefly_NNP ,_, one_CD μg_NN of_IN Poly_NNP (_( A_DT )_) +_NN RNA_NNP
          isolated_VBD from_IN PBMC_NNP of_IN an_DT LGL_NNP leukemia_NN patient_NN and_CC healthy_JJ
          individual_NN was_VBD reverse_VB transcribed_JJ to_TO generate_VB Cy_NNP 3_CD and_CC
          Cy_NNP 5_CD fluorescent_NN labeled_VBD cDNA_NN probes_NNS ._. cDNA_NN probes_NNS were_VBD
          competitively_RB hybridized_JJ to_TO a_DT human_JJ UniGEM-V_NNP cDNA_NN
          microarray_NN containing_VBG approximately_RB 7075_CD immobilized_JJ cDNA_NN
          fragments_NNS (_( 4107_CD for_IN known_VBN genes_NNS and_CC 2968_CD for_IN ESTs_NNP )_) ._.
          Microarrays_NNP were_VBD scanned_JJ in_IN both_DT Cy_NNP 3_CD and_CC Cy_NNP 5_CD channels_NNS
          with_IN an_DT Axon_NNP GenePix_NNP scanner_NN (_( Foster_NNP City_NNP ,_, CA_NNP )_) with_IN a_DT 10_CD
          μm_NN resolution_NN ._. P_NN 1_CD and_CC P_NN 2_CD signals_NNS are_VBP the_DT intensity_NN
          reading_NN obtained_VBN by_IN the_DT scanner_NN for_IN Cy_NNP 3_CD and_CC Cy_NNP 5_CD channels_NNS ._.
          The_DT balanced_JJ differential_NN expression_NN was_VBD calculated_VBN using_VBG
          the_DT ratio_NN between_IN the_DT P_NN 1_CD signal_NN (_( intensity_NN reading_NN for_IN
          probe_NN 1_LS )_) and_CC the_DT balanced_JJ P_NN 2_CD signal_NN (_( intensity_NN reading_NN
          for_IN probe_NN 2_CD adjusted_VBN using_VBG the_DT balanced_JJ coefficient_NN )_)
          Incyte_NNP GEMtools_NNP software_NN (_( Incyte_NNP Pharmaceuticals_NNP ,_,
          Inc_NNP ._. ,_, Palo_NNP Alto_NNP ,_, CA_NNP )_) was_VBD used_VBN for_IN image_NN analysis_NN ._. A_DT
          gridding_VBG and_CC region_NN detection_NN algorithm_NN determined_VBD the_DT
          elements_NNS ._. The_DT area_NN surrounding_VBG each_DT element_NN image_NN was_VBD
          used_VBN to_TO calculate_VB a_DT local_JJ background_NN and_CC was_VBD subtracted_VBN
          from_IN the_DT total_JJ element_NN signal_NN ._. Background_NNP subtracted_VBD
          element_NN signals_NNS were_VBD used_VBN to_TO calculate_VB Cy_NNP 3_CD :_: Cy_NNP 5_CD ratio_NN ._. The_DT
          average_NN of_IN the_DT resulting_VBG total_JJ Cy_NNP 3_CD and_CC Cy_NNP 5_CD signal_NN gave_VBD a_DT
          ratio_NN that_WDT was_VBD used_VBN to_TO balance_VB or_CC normalize_VB the_DT
          signals_NNS ._.
        
        
          Oligonucleotide_NNP microarray_NN analysis_NN
          The_DT HU_NNP 6800_CD microarray_NN was_VBD obtained_VBN from_IN Affymetrix_NNP
          (_( Santa_NNP Clara_NNP ,_, CA_NNP )_) ._. Briefly_NNP ,_, total_JJ RNA_NNP isolated_VBD from_IN
          normal_JJ PBMC_NNP and_CC leukemic_JJ LGL_NNP were_VBD DNase-treated_NNP and_CC
          purified_JJ with_IN a_DT Qiagen_NNP kit_NN (_( Valencia_NNP ,_, CA_NNP )_) ._. Approximately_RB
          10_CD μg_NN of_IN purified_JJ RNA_NNP was_VBD used_VBN to_TO prepare_VB double-stranded_JJ
          cDNA_NN (_( Supercript_NNP GIBCO_NNP /_NN BRL_NNP ,_, Rockville_NNP ,_, MD_NNP )_) using_VBG a_DT T_NN 7_CD
          (_( dT_NN )_) 24_CD primer_NN containing_VBG a_DT T_NN 7_CD RNA_NNP polymerase_NN promoter_NN
          binding_JJ site_NN ._. Biotinylated_NNP complementary_JJ RNA_NNP was_VBD prepared_VBN
          from_IN 10_CD μg_NN of_IN cDNA_NN and_CC then_RB fragmented_VBN to_TO approximately_RB
          50_CD to_TO 100_CD nucleotides_NNS ._. 
          In_IN vitro_NN transcribed_JJ transcripts_NNS
          were_VBD hybridized_JJ to_TO the_DT HU_NNP 6800_CD microarray_NN for_IN 16_CD h_NN at_IN
          45_CD °_NN C_NNP with_IN constant_JJ rotation_NN at_IN 60_CD rpm_NN ._. Chips_NNPS were_VBD washed_VBN
          and_CC stained_JJ by_IN using_VBG the_DT Affymetrix_NNP fluidics_NNS station_NN ._.
          Fluorescence_NNP intensity_NN was_VBD measured_VBN for_IN each_DT chip_NN and_CC
          normalized_JJ to_TO the_DT fluorescence_NN intensity_NN for_IN the_DT entire_JJ
          chip_NN ._.
        
        
          Verification_NNP of_IN the_DT clones_NNS
          GEM_NNP cDNA_NN clones_NNS (_( supplied_VBN as_IN a_DT bacterial_JJ stab_NN )_) were_VBD
          purchased_VBN from_IN IncyteGenomics_NNP and_CC streaked_VBD on_IN LB_NNP agar_NN
          plates_NNS containing_VBG the_DT appropriate_JJ antibiotic_NN ._. Individual_JJ
          colonies_NNS were_VBD picked_VBN and_CC grown_VBN in_IN LB_NNP medium_NN ._. Plasmid_NNP DNA_NNP
          was_VBD isolated_VBN and_CC sequenced_JJ in_IN order_NN to_TO verify_VB the_DT
          sequence_NN identity_NN ._.
        
        
          Northern_JJ blot_NN analysis_NN
          Northern_NNP Blotting_NNP was_VBD performed_VBN as_IN described_VBN ._. Briefly_NNP
          10_CD μg_NN of_IN total_JJ RNA_NNP from_IN each_DT sample_NN was_VBD denatured_JJ at_IN 65_CD °_NN C_NNP
          in_IN RNA_NNP loading_NN buffer_NN ,_, electrophoresed_JJ in_IN a_DT 1_CD %_NN agarose_NN
          gel_NN containing_VBG 2_CD ._. 2_CD M_NNP formaldehyde_NN ,_, then_RB blotted_JJ onto_IN a_DT
          Nytran_NNP membrane_NN (_( Schleicher_NNP &_CC Schuell_NNP ,_, Inc_NNP ,_, Keene_NNP ,_,
          N_NNP ._. H_NNP )_) ._. The_DT RNA_NNP was_VBD fixed_VBN to_TO the_DT membrane_NN by_IN UV_NNP
          cross-linking_JJ ._. cDNA_NN was_VBD labeled_VBN with_IN [_NN 32_CD P_NN ]_NN and_CC purified_JJ
          using_VBG Nick_NNP columns_NNS (_( Amersham_NNP Pharmacia_NNP Biotech_NNP AB_NNP ,_,
          Piscataway_NNP ,_, NJ_NNP )_) ._. Hybridization_NNP and_CC washing_NN of_IN the_DT blots_NNS
          were_VBD performed_VBN as_IN described_VBN by_IN Engler-_NNP Blum_NNP et_CC al_NN [_NN 15_CD ]_NN
          ._.
        
        
          RNase_NNP protection_NN assay_NN (_( RPA_NNP )_)
          RPAs_NNP were_VBD performed_VBN using_VBG the_DT RNA_NNP isolated_VBD from_IN
          leukemic_JJ LGL_NNP ,_, normal_JJ PBMC_NNP and_CC normal_JJ PBMC_NNP activated_VBN by_IN
          IL-_NNP 2_CD and_CC PHA_NNP ._. Five_CD μg_NN of_IN total_JJ RNA_NNP was_VBD hybridized_JJ to_TO the_DT 
          in_IN vitro_NN transcribed_JJ hAPO-_NN 4_CD probe_NN
          set_VBN (_( PharMingen_NNP ,_, SanDiego_NNP ,_, CA_NNP )_) ,_, and_CC the_DT RPA_NNP assay_NN was_VBD
          performed_VBN according_VBG to_TO the_DT manufacturer_NN 's_POS protocol_NN ._. After_IN
          the_DT assay_NN ,_, the_DT samples_NNS were_VBD resolved_VBN on_IN a_DT 5_CD %_NN
          polyacrylamide_NN gel_NN ._. The_DT gel_NN was_VBD dried_VBN and_CC exposed_VBN to_TO
          X-_NNP ray_NN film_NN ._. After_IN developing_VBG the_DT film_NN ,_, the_DT bands_NNS were_VBD
          quantitated_JJ by_IN using_VBG the_DT ImageQuant_NNP program_NN and_CC
          normalized_JJ with_IN the_DT housekeeping_NN gene_NN ,_, L_NNP 32_CD ._.
        
        
          Western_JJ immunoblot_NN analysis_NN
          Cells_NNP were_VBD lysed_JJ in_IN a_DT buffer_NN containing_VBG 50_CD mM_NN Tris-_NNP HCl_NNP
          (_( pH_NN 7_CD ._. 6_CD )_) ,_, 5_CD mM_NN EDTA_NNP ,_, 150_CD mM_NN NaCl_NNP ,_, 0_CD ._. 5_CD %_NN NP-_NNP 40_CD ,_, and_CC 0_CD ._. 5_CD %_NN
          Triton_NNP X-_NNP 100_CD containing_VBG 1_CD μg_NN /_NN ml_NN leupeptin_NN ,_, aprotinin_NN and_CC
          antipain_NN ;_: 1_CD mM_NN sodiumorthovanadate_NN ;_: and_CC 0_CD ._. 5_CD mM_NN PMSF_NNP (_( all_DT
          reagents_NNS were_VBD obtained_VBN from_IN Sigma_NNP Chemical_NNP Co_NNP ._. )_) ._.
          Twenty-five_CD μg_NN of_IN total_JJ protein_NN from_IN each_DT sample_NN was_VBD
          subjected_VBN to_TO 10_CD %_NN SDS-PAGE_NNP ._. Then_RB the_DT proteins_NNS were_VBD
          transferred_VBN to_TO a_DT membrane_NN and_CC Western_NNP blotting_VBG was_VBD
          performed_VBN using_VBG the_DT monoclonal_NN antibody_NN for_IN PAC-_NNP 1_CD and_CC
          A_DT 20_CD ,_, followed_VBN by_IN the_DT ECL_NNP technique_NN as_IN recommended_VBN by_IN the_DT
          manufacturer_NN (_( Amersham_NNP Biosciences_NNP ,_, Piscataway_NNP ,_, NJ_NNP )_) ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        RK_NNP conceived_VBD of_IN the_DT study_NN along_IN with_IN TPL_NNP ,_, isolated_VBN ,_,
        purified_JJ RNA_NNP from_IN the_DT samples_NNS for_IN microarray_NN and_CC performed_VBD
        all_PDT the_DT experiments_NNS to_TO validate_NN the_DT microarray_NN data_NN and_CC
        analysed_JJ the_DT data_NNS and_CC drafted_VBD the_DT manuscript_NN ._. SJY_NNP verified_VBN
        the_DT microarray_NN data_NN and_CC participated_VBD in_IN validation_NN of_IN the_DT
        microarray_NN ._. SM_NNP performed_VBD microarray_NN analysis_NN and_CC analyzed_VBD
        the_DT data_NNS and_CC TPL_NNP conceived_VBD of_IN the_DT study_NN ,_, and_CC participated_VBD
        in_IN its_PRP$ design_NN and_CC coordination_NN ._.
      
    
  
